

Pre-Eclampsia - Pipeline Insight, 2021

<https://marketpublishers.com/r/PC1EE77FF641EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PC1EE77FF641EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Pre-Eclampsia – Pipeline Insight, 2021," report provides comprehensive insights about companies and pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pre-Eclampsia Understanding

Pre-Eclampsia : Overview

Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Pre-eclampsia is a combination of hypertension (raised blood pressure) and proteinuria in pregnancy (the presence of protein in your urine). It generally develops during the third trimester. The condition affects around 5% to 8% of pregnancies and presents serious health consequences to mothers and babies. There is not a single cause, but some potential causes include: genetic factors and blood vessel problems. Left untreated, preeclampsia can lead to serious — even fatal — complications for both mother and baby.

"Abnormal Glucose Tolerance - Pipeline Insight, 2021" report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pre-Eclampsia Emerging Drugs Chapters

This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pre-Eclampsia Emerging Drugs

KW3357: Kyowa Kirin Co., Ltd.

KW-3357 is an antithrombin (AT) drug created through the technology of recombinant DNA and sugar-chain control, which is a recombinant AT preparation with the same amino acid sequence and the same type of sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the coagulation factor of proteolytic enzyme. In Japan, KW-3357 has been approved for the treatments of thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) since July, 2015 and commercialized under the brand name of ACOALAN. KW3357 is currently in phase III stage of development by Kyowan Kirin Co.,Ltd in collaboration with Japan Blood Products Organization for Preeclampsia.

rhC1INH protein replacement therapy: Pharming Group

Pharming Group is developing a rhC1INH protein replacement therapy for the treatment of pre-eclampsia. Pre-eclampsia is a life-threatening multisystem disorder in pregnancies leading to maternal and neonatal mortality and morbidity, usually first appearing as hypertension and proteinuria. Pharming Group had initiated the therapy in 2019 and was in phase I/II of development, but was halted due to COVID-19.

Further product details are provided in the report.....

Pre-Eclampsia : Therapeutic Assessment

This segment of the report provides insights about the different Pre-Eclampsia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pre-Eclampsia

There are several companies which are developing the therapies for Pre-Eclampsia . The companies which have their Pre-Eclampsia drug candidates in the mid to advanced stage, i.e. phase III include, Kyowa Kirin Co.,Ltd. and others.

Phases

DelveInsight's report covers products under different phases of clinical development like

- Late-stage products (Phase III)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Subcutaneous

- Intravenous

- Oral

Molecule Type

Products have been categorized under various Molecule types such as

Replacement Therapy

Physiological Saline

Antihypertensive

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pre-Eclampsia : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia .

Pre-Eclampsia Report Insights

Pre-Eclampsia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pre-Eclampsia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pre-Eclampsia drugs?

How many Pre-Eclampsia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pre-Eclampsia ?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pre-Eclampsia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pre-Eclampsia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Kyowa Kirin Co., Ltd

Pharming Group

Amag Pharmaceuticals

MirZyme

Key Products

KW3357

rhC1INH protein replacement therapy

AMAG-423

MZe686

Contents

- Introduction
- Executive Summary
- Pre-Eclampsia : Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Pre-Eclampsia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Pre-Eclampsia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Pre-Eclampsia Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- KW 3357: Kyowa Kirin Co., Ltd.
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I/II)
 - Comparative Analysis
- rhC1INH protein replacement therapy: Pharming Group
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Pre-Eclampsia Key Companies

Pre-Eclampsia Key Products

Pre-Eclampsia - Unmet Needs

Pre-Eclampsia - Market Drivers and Barriers

Pre-Eclampsia - Future Perspectives and Conclusion

Pre-Eclampsia Analyst Views

Pre-Eclampsia Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Pre-Eclampsia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Pre-Eclampsia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Pre-Eclampsia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PC1EE77FF641EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC1EE77FF641EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970